Osteopathy in mild adrenal Cushing's syndrome and Cushing disease

Best Pract Res Clin Endocrinol Metab. 2021 Mar;35(2):101515. doi: 10.1016/j.beem.2021.101515. Epub 2021 Mar 10.

Abstract

Pathophysiology and effects of endogenous glucocorticoid (GC) excess on skeletal endpoints as well as awareness and management of bone fragility are reviewed. Cushing's syndrome (CS) increase the risk of fracture affecting prevalently bone quality. Bone antiresorptive agents (SERMs, bisphosphonates and denosumab) as well as teriparatide increase bone mineral density and in some instances reduce fracture risk. Awareness and management of bone health in CS can be improved.

Keywords: adrenal incidentaloma; bone mineral density; bone quality; cushing disease; fractures; glucocorticoids.

Publication types

  • Review

MeSH terms

  • Bone Density
  • Bone Density Conservation Agents* / therapeutic use
  • Cushing Syndrome* / complications
  • Humans
  • Osteoporosis* / drug therapy
  • Osteoporosis* / epidemiology
  • Osteoporosis* / etiology
  • Pituitary ACTH Hypersecretion* / complications

Substances

  • Bone Density Conservation Agents